12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Karus, The Babraham Institute deal

Karus and the institute will characterize the effect of undisclosed inhibitors of the p110 beta and delta isoforms of...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >